Drug Profile
Vapendavir - Altesa Biosceinces/Vaxart
Alternative Names: BTA-798Latest Information Update: 07 Mar 2024
Price :
$50
*
At a glance
- Originator Biota Holdings
- Developer Altesa Biosciences; Aviragen Therapeutics; Biota Pharmaceuticals; Vaxart
- Class Antivirals; Benzoxazoles; Ethers; Piperidines; Pyridazines; Small molecules
- Mechanism of Action Capsid protein inhibitors; Rhinovirus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Rhinovirus infections
Most Recent Events
- 20 Nov 2023 Phase-II clinical trials in Rhinovirus infections in United Kingdom (PO) (NCT06149494)
- 19 May 2023 Altesa initiates a phase I pharmacokinetics and food effect study in healthy subjects and subjects with COPD in USA (PO) (NCT05962645)
- 26 May 2022 US FDA approves the investigational new drug application (IND) for vapendavir in Rhinovirus infections